EVAX - Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept | Benzinga
- Proof of Concept – Evaxion's AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
- Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies
COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.
Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company's proprietary AI target discovery and development platform, AI-Immunology™. Based upon a novel source of targets, endogenous retroviruses (ERVs), combined with unique data insights, Evaxion has discovered a novel concept for precision vaccines in hematological malignancies and selected solid cancers.
Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies. The discovery will potentially allow ...